The study introduces a finite element analysis (FEA)-guided co-design framework for developing separable bubble microneedles (BMNs) that optimize geometry and cavity parameters for controlled tip separation and robust insertion. The research demonstrated that minoxidil sulfate-loaded BMNs (MXS-BMNs) and insulin-loaded BMNs (INS-BMNs) achieved effective transdermal and sublingual delivery, respectively. MXS-BMNs showed a sevenfold increase in minoxidil permeation compared to topical gel and accelerated hair regrowth in mice, while INS-BMNs provided rapid glucose reduction in diabetic rats. The FEA predictions closely matched experimental results, confirming the framework's efficacy in reducing empirical iteration and expediting BMN development for rapid drug delivery.
The study introduces a finite element analysis (FEA)-guided co-design framework for developing separable bubble microneedles (BMNs) that optimize geometry and cavity parameters for controlled tip separation and robust insertion. The research demonstrated that minoxidil sulfate-loaded BMNs (MXS-BMNs) and insulin-loaded BMNs (INS-BMNs) achieved effective transdermal and sublingual delivery, respectively, with separation forces closely matching FEA predictions and axial strengths surpassing skin and mucosa penetration thresholds. In vivo tests showed MXS-BMNs significantly enhanced hair regrowth in mice, while INS-BMNs effectively lowered glucose levels in diabetic rats. This approach reduces empirical iteration, facilitating the rapid development of efficient microneedle systems for drug delivery.
77 citations
,
January 2015 in “International Journal of Biological Macromolecules” Chitosan nanoparticles improve minoxidil delivery to hair follicles for better alopecia treatment.
45 citations
,
August 2011 in “Journal of Microencapsulation” Chitosan microparticles improve minoxidil sulphate delivery, potentially reducing daily applications.
32 citations
,
March 2013 in “Journal of Pharmaceutical Sciences” Iontophoresis improves minoxidil delivery for alopecia treatment.
25 citations
,
July 2015 in “Colloids and Surfaces B: Biointerfaces” Iontophoresis improves minoxidil delivery to hair follicles for hair loss treatment.
5 citations
,
January 2018 in “Skin appendage disorders” Minoxidil base is preferred for hair loss treatment, but minoxidil sulfate may be an alternative for unresponsive patients.
January 2026 in “Journal of Applied Polymer Science” The new fiber offers long-lasting minoxidil release and can be used in wigs for hair treatment and coverage.
April 2025 in “International Journal of Pharmaceutics” Liposomes improve minoxidil delivery to hair follicles, enhancing treatment for hair loss.
3 citations
,
May 1994 in “Journal of Pharmacology and Experimental Therapeutics” Minoxidil sulfate affects Cl channels, while minoxidil affects K channels in cells.
December 2009 in “Digital Library of Theses and Dissertations (Universidade de São Paulo)” Iontophoresis and chitosan microparticles improve minoxidil delivery for hair loss treatment.
33 citations
,
October 2016 in “European Journal of Pharmaceutical Sciences” Effervescent formulations may improve minoxidil delivery, increasing effectiveness and reducing applications needed.
2 citations
,
August 2016 in “Química Nova” Using iontophoresis on minoxidil sulphate-loaded chitosan nanoparticles increases drug release but reduces its targeting to hair follicles.
158 citations
,
December 2002 in “Development” Msx2-deficient mice experience irregular hair growth and loss due to disrupted hair cycle phases.
694 citations
,
April 2000 in “Nature genetics” Msx2 deficiency in mice leads to bone growth and organ development problems.
117 citations
,
August 2019 in “Drug Design Development and Therapy” Minoxidil effectively treats hair loss, but use cautiously and monitor side effects.
104 citations
,
March 2014 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” DHT may increase the risk of heart disease and death in elderly men.
34 citations
,
February 1992 in “Naunyn-schmiedebergs Archives of Pharmacology” Tedisamil and glibenclamide affect cromakalim and minoxidil sulphate differently in rat aorta.
22 citations
,
November 2018 in “Brazilian Journal of Pharmaceutical Sciences” New physical methods like electrical currents, ultrasound, and microneedles show promise for improving drug delivery through the skin.
9 citations
,
May 2020 in “Journal of Pharmaceutical and Biomedical Analysis” Method measures latanoprost and minoxidil in skin accurately and precisely.
January 2025 in “Biomedical Engineering Letters” MXD@CP could be a promising new topical treatment for hair loss.
18 citations
,
June 2018 in “Journal of Dental Research” Msx2 is essential for proper enamel formation by preventing abnormal cell transformation.
221 citations
,
July 2012 in “Proceedings of the National Academy of Sciences of the United States of America” BMAL1 controls skin cell growth and UV damage risk, peaking at night.
January 2024 in “Frontiers in Bioengineering and Biotechnology” A new method using stem cell membranes to deliver Minoxidil improved hair growth in mice better than Minoxidil alone.
August 2024 in “Journal of Drug Delivery Science and Technology” The new minoxidil formulation could better promote hair growth for treating androgenic alopecia.
2 citations
,
March 2005 in “Cancer biology & therapy” Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.
49 citations
,
August 1999 in “Journal of Investigative Dermatology” Overexpressing the MSX-2 gene in mice causes skin and hair growth issues.
234 citations
,
April 2000 in “Gene” Msx and Dlx genes are crucial for development, controlling cell behaviors like growth and differentiation through their roles as gene regulators.
2 citations
,
April 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” The skin's basement membrane is specially designed to support different types of connections between skin layers and hair follicles.
September 2013 in “Oncology Times” Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.